MiMedx Group (MDXG) Receives a Buy from Lake Street
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on MiMedx Group, with a price target of $12.00. The company’s shares closed yesterday at $7.31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Takkinen covers the Healthcare sector, focusing on stocks such as Sight Sciences, Stereotaxis, and ClearPoint Neuro. According to TipRanks, Takkinen has an average return of 3.4% and a 40.11% success rate on recommended stocks.
MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $12.00.
The company has a one-year high of $10.14 and a one-year low of $5.47. Currently, MiMedx Group has an average volume of 738.9K.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.